Balance Wealth
BIO icon

Balance Wealth’s Bio-Rad Laboratories Class A BIO Stock Holding History

Balance Wealth’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$340 Buy
+1
New +$349 ﹤0.01% 914

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $63.7B AUM 20.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Ariel Investments
Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return

Balance Wealth's BIO Position: Q3 2026 in Review

Balance Wealth opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2026: 1 share worth $340. The stake represents ﹤0.01% of the portfolio and ranks #914 among its holdings.

325 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • Balance Wealth held 1 share of Bio-Rad Laboratories Class A worth $340 as of Q3 2026.
  • Bio-Rad Laboratories Class A was a new Balance Wealth position in Q3 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Balance Wealth's portfolio in Q3 2026, its #914 holding.
  • 325 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Balance Wealth's 13F filing for Q3 2026, filed 27 Oct 2026.